|
|
|
|
|
20.07.26 - 19:21
|
Sanofi Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi auf "Neutral" belassen. Richard Vosser verglich in einer am Montag vorliegenden Studie seine eigenen Schätzungen mit den Konsensschätzungen - mit dem Fazit, dass er beim ......
|
|
|
20.07.26 - 17:51
|
Eurofins Scientific SE: Weekly Report on Share Repurchases from 13th July to 17th July 2026 (Business Wire)
|
|
|
LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific SE (Paris:ERF):
Weekly report on share repurchases from 13th July to 17th July 2026
Name of the Issuer
Identify code of the Issuer
Transaction day
Identify code of the financial instrument
Total daily volume (in number of shares)
Daily weighted average purchase price of the shares
Market (MIC Code)
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
13/07/2026
FR0014000MR3
15 000
69.1984
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
13/07/2026
FR0014000MR3
5 000
69.1700
CEUX
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
14/07/2026
FR0014000MR3
5 000
68.9705
CEUX
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
14/07/2026
FR0014000MR3
15 000
68.8830
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
15/07/2026
FR0014000MR3
5 000
69.3744
CEUX
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
15/07/2026
FR0014000MR3
15 000
69.2601
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
16/07/2026
FR0014000MR3
5 000
69.0555
CEUX
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
16/07/2026
FR001400...
|
|
|
|
|
|
|
20.07.26 - 07:21
|
Eurofins Agrees to Acquire Element Materials Technology′s Life Sciences Testing Services Business in North America (Business Wire)
|
|
|
LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific (EUFI.PA) (Paris:ERF), a global scientific leader in bioanalytical testing, has reached an agreement with Element Materials Technology (“Element”) to acquire its Life Sciences Testing Services business in North America, for an enterprise value of $400m. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in Q4 2026.
Element's North America Life Sciences Testing Services includes a range of Biopharma product testing, Environmental testing and Food testing services, offered by a network of 27 laboratories and facilities. It employs approximately 750 FTEs, and is expected to generate annual revenues of over $150m in 2026, with profitability similar to the Eurofins Group average.
This addition to Eurofins' BioPharma and Life businesses in North America will expand the geographic presence of Eurofins' laboratories network into certain key regions of the United States and Canada wher...
|
|
|
|
|
17.07.26 - 18:03
|
ADOCIA Announces Half-Year Report on Adocia′s Liquidity Agreement with Kepler Capital Markets (Business Wire)
|
|
|
LYON, France--(BUSINESS WIRE)--#BIOTECH--Regulatory News:
Under the liquidity agreement entrusted by Adocia (Euronext Paris: FR0011184241 – ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on June 30, 2026 :
Number of shares: 45,699
Cash balance of the liquidity account: € 126,636.84
During the 1st half of 2026, a total of:
Buy-side
298,013 shares
€ 1,619,929.17
1,640 transactions
Sell-side
279,243 shares
€ 1,571,808.67
1,524 transactions
The following resources appeared on the last half year statement on December 31, 2025 on the liquidity account:
Number of shares: 26,929
Cash balance of the liquidity account: € 173,857.41
The following resources appeared on the liquidity account when the activity started:
Number of shares: 15,026
Cash balance of the liquidity account: € 300,000.00
The liquidity agreement complies with AMF Decision n° 2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market pr...
|
|
|
|
|
17.07.26 - 12:33
|
Aqemia and Sanofi Expand Their Research Collaboration (Business Wire)
|
|
|
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023PARIS & LONDON--(BUSINESS WIRE)--#DrugDiscovery--Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment.
The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi's targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi ...
|
|
|
17.07.26 - 11:30
|
Abivax-Aktie: Bericht bestätigt neue Übernahmegespräche (Sharedeals)
|
|
|
Die Übernahmefantasie rund um Abivax erhält neue Impulse. Nachdem zuletzt mehrere Analysten ihre Kursziele für die Aktie angehoben und auf das erhebliche Potenzial des Wirkstoffkandidaten Obefazimod verwiesen hatten, sorgt nun ein neuer Bericht des französischen Informationsdienstes La Lettre für neue Spekulationen. Demnach hat das Biotech-Unternehmen seine US-Investmentbank Centerview Partners erneut eingeschaltet, um Gespräche mit potenziellen […]
The post Abivax-Aktie: Bericht bestätigt neue Übernahmegespräche first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.07.26 - 18:39
|
Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France (Business Wire)
|
|
|
The first half 2026 reported revenue is the first without the negative impact of early access rebates
Reported revenue does not include royalties to be received from commercial partners on Sibnayal® sales
In the French market alone, Sibnayal® sales grew by 41% in volume
Reimbursement of Likozam® has high impact on its sales growth
PARIS--(BUSINESS WIRE)--Regulatory News:
Advicenne S.A. (“Advicenne” or the “Company”) (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, today announces its net revenue for the first half of 2026, more than doubled to €2.7 million, the first one reported without the significant negative impact of the early access clawbacks. The reported revenue does not include royalties to be received from its commercial partners on Sibnayal®'s sales.
The very significant increase in activity over the past half-year is explained by the pric...
|
|
|
|
|
16.07.26 - 17:51
|
SMAIO Reports Sales for the First Half of 2026 (Business Wire)
|
|
|
Up 3% to €5.1m, first-half sales exceeded the €5m mark for the first time, despite four months of temporary absence of one of the top-performing surgeons in the United States
U.S. sales rose by 10% to $4.5m, or 3% to €3.9m
Continued expansion of the network in the United States, with 5 new centers added to the network and 13 new surgeons who have performed their first implants
As of the end of June 2026, SMAIO's solutions (patient-specific rods K-ROD or complete Kheiron fixation system) have been registered at more than 20 centers in the United States, representing more than 34 surgeons who should contribute to sustained and diversified long-term sales growth in North America
Strong cash position of €7.0m as of June 30, 2026, enabling the company to confidently pursue its development strategy
Webconference in French today at 6 pm CEST:
REGISTER HEREDALLAS & LYON, France--(BUSINESS WIRE)--Regulatory News:
SMAIO (Software, Machines and Adaptive Implants in Orthopaedics – Euronext Growth Paris, ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
